Getting thin to succeed in a fat-phobic society is still an understandable individual solution to a structural problem ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

You know you’re in trouble when the pharmacy worker catches your eye and lowers her voice: “You know how much this costs, ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Novo Nordisk A/S (NYSE: NVO) has reported that it retains about sixty percent of the list price of Ozempic and Wegovy, its ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Thirty-nine percent of millennials and 35% of Gen Z say access to weight loss drugs would improve their job satisfaction or ...

Academic science is fertilizer of the economy. It creates soil where innovation thrive. Some who don’t know about how things ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric ...